EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study

Sammy Huygens iD, Tim Preijers iD, Francis H Swaneveld, Ilona Kleine Budde, Corine H GeurtsvanKessel iD, Birgit C P Koch iD, Bart J A Rijnders iD

Clinical Pharmacokinetics · 2024

DOI: 10.1007/s40262-024-01351-w ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Sammy Huygens und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Me…. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, COVID-19 Serotherapy, Immunization, Passive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: During the COVID-19 pandemic, trials on convalescent plasma (ConvP) were performed without preceding dose-finding studies. This study aimed to assess potential protective dosing regimens by constructing a population pharmacokinetic (popPK) model describing anti-SARS-CoV-2 antibody titers following the administration of ConvP or hyperimmune globulins (COVIg). METHODS: Immunocompromised patients, testing negative for anti-SARS-CoV-2 spike antibodies despite vaccination, received a range of anti-SARS-CoV-2 antibodies in the form of COVIg or ConvP infusion. The popPK analysis was performed using NONMEM v7.4. Monte Carlo simulations were performed to assess potential COVIg and ConvP dosing regimens for prevention of COVID-19. RESULTS: Forty-four patients were enrolled, and data from 42 were used for constructing the popPK model. A two-compartment elimination model with mixed residual error best described the Nab-titers after administration. Inter-individual variation was associated to CL (44.3%), V1 (27.3%), and V2 (29.2%). Lean body weight and type of treatment (ConvP/COVIg) were associated with V1 and V2, respectively. Median elimination half-life was 20 days (interquartile range: 17-25 days). Simulations demonstrated that even monthly infusions of 600 mL of the ConvP or COVIg used in this trial would not achieve potentially protective serum antibody titers for > 90% of the time. However, as a result of hybrid immunity and/or repeated vaccination, plasma donors with extremely high antibody titers are now readily available, and a > 90% target attainment should be possible. CONCLUSION: The results of this study may inform future intervention studies on the prophylactic and therapeutic use of antiviral antibodies in the form of ConvP or COVIg. CLINICAL TRIAL REGISTRATION NUMBER: NL9379 (The Netherlands Trial Register).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralCOVID-19COVID-19 SerotherapyImmunization, PassiveAdultAgedFemaleHumansMaleMiddle AgedAntibodies, NeutralizingImmunocompromised HostModels, BiologicalMonte Carlo Method

Substanzen

Antibodies, NeutralizingAntibodies, Viral

Autor:innen und Institutionen

  • Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlan…
  • Department of Hospital Pharmacy, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Rotterdam Clinical Pharmacometrics group, Rotterdam, The Netherlands.
  • Unit of Transfusion Medicine, Sanquin Blood Supply Foundation, 1066 CX, Amsterdam, The Netherlands.
  • Clinical Operations, Prothya Biosolutions, 1066 CX, Amsterdam, The Netherlands.
  • Department of Viroscience, Erasmus University Medical Center Rotterdam, WHO Collaborating Centre for Arbovirus and Viral Hemorrhagic Fever Reference and Research, Rotterdam, The Netherlands.

ORCID-Profile: Sammy Huygens, Tim Preijers, Corine H GeurtsvanKessel, Birgit C P Koch, Bart J A Rijnders

Förderung

  • ZonMw

Zitieren

APA

Huygens, S., Preijers, T., Swaneveld, F. H., Kleine Budde, I., GeurtsvanKessel, C. H., Koch, B. C. P., & Rijnders, B. J. A. (2024). Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01351-w

Vancouver

Huygens S, Preijers T, Swaneveld FH, Kleine Budde I, GeurtsvanKessel CH, Koch BCP, et al. Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01351-w

BibTeX
@article{Huygens2024,
  author = {Huygens, Sammy and Preijers, Tim and Swaneveld, Francis H and Kleine Budde, Ilona and GeurtsvanKessel, Corine H and Koch, Birgit C P and Rijnders, Bart J A},
  title = {Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study},
  journal = {Clinical Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s40262-024-01351-w}
}
Kostenlos starten →